Quantitation of ^99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis

References

• Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6:214–220.
   PubMed Web of Science ®Google Scholar
• Sipe JD, Benson MD, Buxbaum JD, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification. International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016;23:209–213.
   PubMed Web of Science ®Google Scholar
• Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol. 2003;17:909–927.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141–157.
   PubMed Web of Science ®Google Scholar
• Dungu JN, Anderson LJ, Whelan CJ, et al. Cardiac transthyretin amyloidosis. Heart. 2012;98:1546–1554.
   PubMed Web of Science ®Google Scholar
• Mirzoyev SA, Edwards WD, Mohammed SF, et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation. 2014;2:113.
   Google Scholar
• Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232–239.
   PubMed Web of Science ®Google Scholar
• Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem. 1962;10:355–364.
   Web of Science ®Google Scholar
• Fine NM, Arruda-Olson AM, Dispenzieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113:1177–1723.
   Web of Science ®Google Scholar
• Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015;128:1275–1280.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786–1791.
   PubMed Web of Science ®Google Scholar
• Sachchithanantham S, Wechalekar AD. Imaging in systemic amyloidosis. Br Med Bull. 2013;107:41–56.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–2654.
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047–2060.
   PubMed Web of Science ®Google Scholar
• Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570–1579.
   PubMed Web of Science ®Google Scholar
• Austin BA, Tang WHW, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2:1369–1377.
   PubMed Web of Science ®Google Scholar
• Dungu JN, Valencia O, Pinney JH, et al . CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7:133–142.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508–513.
   PubMed Web of Science ®Google Scholar
• Hawkins P. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens. 2002;11:649–655.
   PubMed Web of Science ®Google Scholar
• Glaudemans AWJM, Slart RHJA, Zeebregts CJ, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2009;36:702–714.
   PubMed Web of Science ®Google Scholar
• VanAntwerp JD, O'Mara RE, Pitt MJ, et al. Technetium-99m-diphosphonate accumulation in amyloid. J Nucl Med. 1975;16:238–240.
   PubMed Web of Science ®Google Scholar
• Ali A, Turner DA, Rosenbush SW, et al. Bone scintigram in cardiac amyloidosis: a case report. Clin Nucl Med. 1981;6:105–108.
   PubMedGoogle Scholar
• Bokhari S, Shahzad R, Castaño A, et al. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol. 2014;21:175–184.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–1084.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Guidalotti P, Salvi F, et al. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol 2008;51:1509–1510.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38:470–478.
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castaño A, Pozniakoff T, et al. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201.
   PubMed Web of Science ®Google Scholar
• Quarta CC, Guidalotti PL, Longhi S, et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc Imaging. 2012;5:755–758.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4:659–670.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–2466.
   PubMed Web of Science ®Google Scholar
• Rosset A, Spadola L, Ratib O . OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging. 2004;17:205–216.
   PubMed Web of Science ®Google Scholar
• Cerqueira MD, Weissman NJ, Dilsizian V, et al . Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539–542.
   PubMed Web of Science ®Google Scholar
• Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18:1344–1350.
   PubMed Web of Science ®Google Scholar
• Hutt DF, Quigley A-M, Page J, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15:1289–1298.
   PubMed Web of Science ®Google Scholar
• Cappelli F, Gallini C, Costanzo EN, et al. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon. Int J Cardiol. 2018;254:346–350.
   PubMed Web of Science ®Google Scholar
• Castaño A, DeLuca A, Weinberg R, et al. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol. 2016;23:1355–1363.
   PubMed Web of Science ®Google Scholar